---
title: "Royalty Pharma declares third quarter 2026 dividend | RPRX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293071771.md"
description: "Royalty Pharma plc (Nasdaq: RPRX) announced that its board of directors approved a third-quarter 2026 dividend of $0.235 per Class A ordinary share. The payment is scheduled for September 10, 2026, to shareholders of record as of August 14, 2026."
datetime: "2026-07-17T12:15:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293071771.md)
  - [en](https://longbridge.com/en/news/293071771.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293071771.md)
---

# Royalty Pharma declares third quarter 2026 dividend | RPRX Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.

The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.

**About Royalty Pharma plc  
**Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com.

**Royalty Pharma Investor Relations and Communications  
**+1 (212) 883-6772  
ir@royaltypharma.com

### Related Stocks

- [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [ALPMY.US](https://longbridge.com/en/quote/ALPMY.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [Dai ichi Life Insurance Company Ltd Has $6.19 Million Stock Position in Royalty Pharma PLC $RPRX](https://longbridge.com/en/news/293839172.md)
- [CI Investments Inc. Has $8.33 Million Stock Holdings in Royalty Pharma PLC $RPRX](https://longbridge.com/en/news/293720828.md)
- [Why Biogen stock topped the market today](https://longbridge.com/en/news/294280002.md)
- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [Biogen Q2 revenue beats expectations on strong product demand](https://longbridge.com/en/news/294189729.md)